Peptide Initiative

Peptide profile · Cosmetic

Acetyl Hexapeptide-3 (Argireline)

SNARE complex inhibitor that reduces expression wrinkles through topical neuromuscular modulation — the 'Botox in a bottle' peptide.

Limited human trialsResearch compound
Topical stability dependent on formulation; methionine residue susceptible to oxidation; stable at pH 5.5-7.7Half-life
Limited skin penetrationBioavailability (0.22-0.54%); primarily acts at stratum corneum and superficial epidermis; O/W emulsions enhance delivery
887.0Molecular weight, Da

Molecular formula

C35H62N14O11S

CAS number
616204-22-9
PubChem
71587772
Developed · 1999
Antonio Ferrer Montiel and research team, University of California San Diego / University of Elche, Spain

Amino acid sequence

Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (Ac-EEMQRR-NH2), modeled on the N-terminal domain of SNAP-25

Expression Wrinkle ReductionIn a 4-week placebo-controlled trial on crow's-feet (periorbital) wrinkles, overall anti-wrinkle efficacy was 48.9% with argireline versus 0% with placebo, and every objective skin-roughness measure fell . It works by interfering with the SNARE complex that drives neurotransmitter release .

8.5

Non-Invasive TreatmentProvides botulinum toxin-like wrinkle reduction mechanism in a topical format — no needles, no neurotoxin, no downtime .

9.2

Safety ProfileCell-culture testing found significant cytotoxicity only at concentrations 18 to 10,000 times higher than the reference drug doxorubicin ; no serious adverse effects have been reported in clinical trials.

9.5

Ratings out of 10.

5 % – 10 %

Every documented dose level

PhaseDoseFrequency
Days 28-305-10% concentration (cream or serum)Twice daily (morning and evening)
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for individuals seeking non-invasive reduction of expression lines and dynamic wrinkles & those with needle phobia who want botulinum toxin-like effects without injections

Best for

  • Individuals seeking non-invasive reduction of expression lines and dynamic wrinkles

    Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on individuals seeking non-invasive reduction of expression lines and dynamic wrinkles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Those with needle phobia who want botulinum toxin-like effects without injections

    Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on those with needle phobia who want botulinum toxin-like effects without injections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • People targeting crow's feet, forehead lines, and glabellar creases

    Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on people targeting crow's feet, forehead lines, and glabellar creases. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Individuals looking for preventive anti-wrinkle treatment to slow expression line formation

    Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on individuals looking for preventive anti-wrinkle treatment to slow expression line formation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for cosmetic supportConsult your healthcare provider for alternatives to Acetyl Hexapeptide-3 (Argireline) based on your specific needs and medical history
Alternative cosmetic peptidesGHK-Cu (Copper Peptide)Argireline (Acetyl Hexapeptide-3)Matrixyl (Palmitoyl Pentapeptide-4)
Non-peptide cosmetic approachesRetinol/RetinoidsHyaluronic acid serumsVitamin C serums

Do not use if

  • Known hypersensitivity to acetyl hexapeptide-3 or formulation components
  • Active skin infections or open wounds at the application site
  • No known systemic contraindications at cosmetic concentrations
  • Use with caution in individuals with neuromuscular disorders (theoretical concern)

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Acetyl Hexapeptide-3 (Argireline) use
  • You have any chronic health conditions that require regular monitoring

Route

Acetyl Hexapeptide-3 (Argireline) is administered Topical—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The Acetyl Hexapeptide-3 (Argireline) dosing protocol covers how it is taken.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Acetyl Hexapeptide-3 demonstrates an excellent safety profile for topical cosmetic use with no serious adverse events reported in clinical studies.

At the 10% concentrations used in cosmetic formulations, systemic absorption is minimal and no neurotoxicity has been observed despite its mechanism of action on the neuromuscular junction.

In cell-culture testing, significant cytotoxicity appeared only at concentrations 18 to 10,000 times higher than the reference drug doxorubicin .

Primary concerns are limited to local skin irritation in sensitive individuals, such as mild erythema, transient stinging, or contact dermatitis in those with peptide hypersensitivity.

Evidence comes from multiple clinical studies demonstrating safety at cosmetic concentrations, including 4-week dermatological safety trials showing no systemic toxicity or significant adverse effects.

The mechanism of action is well-characterized in vitro and validated through efficacy studies. Data suggests the peptide's large molecular size and poor transepidermal penetration provide a natural safety barrier, preventing systemic effects even with prolonged topical use.


Common side effects · experienced by some users

Mild Skin Irritation

Rare mild irritation in sensitive individuals, typically during initial use. Generally self-resolving.

Management
Start with once daily application. If persistent, reduce concentration or discontinue.

Transient Redness

Temporary redness at application site, particularly on thin or sensitive periorbital skin.

Management
Patch test before full application. Allow skin to acclimate over first few days.

Slight Dryness

Minor dryness when peptide solution is used without adequate moisturization in dry environments.

Management
Always follow with a hydrating moisturizer or use Argireline in a cream-based formulation.

Stinging on Compromised Skin

Brief stinging if applied to areas where skin barrier is disrupted (after exfoliation or sun exposure).

Management
Avoid application on freshly exfoliated or sunburned skin. Wait for barrier recovery before use.

Serious side effects

Allergic Contact Dermatitis

Rare but documented cases of allergic sensitization to the peptide or formulation components causing contact dermatitis with inflammation, itching, and potential secondary infection.

Management
Perform patch test before use; discontinue immediately if allergic reaction develops; apply topical corticosteroids if needed; refer to dermatologist for persistent reactions.

Less commonContact Dermatitis

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Acetyl Hexapeptide-3 (Argireline)
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Acetyl Hexapeptide-3 (Argireline) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeHyaluronic Acid — May be used together under medical guidance.
  • SafeMatrixyl (Palmitoyl Pentapeptide-4) — May be used together under medical guidance.
  • SafeNiacinamide — May be used together under medical guidance.

With medications

  • CautionVitamin C at Very Low pH (<3.5) — Use with caution—discuss with your healthcare provider.
  • CautionBenzoyl Peroxide — Use with caution—discuss with your healthcare provider.
  • CautionStrong AHA/BHA Peels — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Acetyl Hexapeptide-3 (Argireline). Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Limited human trials · first signs weeks 1-2

Evidence level

Limited human trials

60/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Acetyl hexapeptide-3 (Argireline) is a cosmetic peptide that mimics part of the SNAP-25 protein, which botulinum toxin targets.

It interferes with the SNARE protein complex inside nerve endings, reducing acetylcholine release at the neuromuscular junction , reducing muscle contraction that causes expression wrinkles. It works topically without injections, making it a non-invasive Botox alternative .

The deeper mechanism

Acetyl hexapeptide-3 is a synthetic hexapeptide acetylated at the N-terminus that mimics the sequence of SNAP-25 (synaptosome-associated protein of 25 kDa), a target of botulinum neurotoxin cleavage.

The peptide acts as a competitive substrate for SNARE complex formation on presynaptic nerve terminals, inhibiting the fusion of acetylcholine-containing synaptic vesicles with the presynaptic membrane.

This prevents acetylcholine release into the neuromuscular junction without permanently cleaving SNARE proteins (unlike botulinum toxin). Topical penetration is achieved through formulation with permeation enhancers, allowing dermal delivery to motor nerves innervating facial muscles.

Acetyl hexapeptide-3 produces reversible, dose-dependent reduction in muscle contraction and wrinkle depth, with effects building over 4-6 weeks of consistent application.


What to expect

  1. Weeks 1-2

    What you might notice

    • SNARE complex modulation begins at the cellular level
    • Neuromuscular signaling partially reduced in treated areas
    • Surface wrinkle changes not yet visible

    What's normal

    • Full integration of Acetyl Hexapeptide-3 (Argireline) into physiological systems is established
    • Long-term Acetyl Hexapeptide-3 (Argireline) response remains personalized to your physiology
    • Acetyl Hexapeptide-3 (Argireline) tolerance is well-maintained with consistent dosing

    What's next

    • Maintain your established Acetyl Hexapeptide-3 (Argireline) protocol for sustained benefits
    • Continue periodic monitoring to confirm Acetyl Hexapeptide-3 (Argireline) efficacy
    • Review comprehensive Acetyl Hexapeptide-3 (Argireline) response with your provider
  2. Weeks 2-4

    What you might notice

    • Expression lines begin to soften as reduced muscle contraction allows collagen relaxation
    • Clinical data shows measurable roughness and wrinkle depth improvements emerging at 4 weeks

    What's normal

    • Acetyl Hexapeptide-3 (Argireline) is now achieving steady-state pharmacokinetics
    • Measurable changes aligned with Acetyl Hexapeptide-3 (Argireline)'s mechanism may appear
    • Initial adjustment effects typically resolve by this point

    What's next

    • Maintain Acetyl Hexapeptide-3 (Argireline) dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team
  3. Weeks 4-8+

    What you might notice

    • Maximum wrinkle reduction achieved (up to 48.9% improvement)
    • Expression lines appear visibly diminished
    • Continued application maintains results;
    • effects are reversible within 4-8 weeks of discontinuation

    What's normal

    • Characteristic effects of Acetyl Hexapeptide-3 (Argireline) are becoming established
    • Repeated Acetyl Hexapeptide-3 (Argireline) doses show predictable pharmacological effects
    • Acetyl Hexapeptide-3 (Argireline) tolerance patterns are developing normally

    What's next

    • Evaluate Acetyl Hexapeptide-3 (Argireline) efficacy relative to treatment goals
    • Discuss potential protocol adjustments with your healthcare provider
    • Continue regular Acetyl Hexapeptide-3 (Argireline) monitoring at current frequency

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Acetyl Hexapeptide-3 (Argireline) over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

Is Argireline really 'Botox in a bottle'?

Argireline targets the same biological mechanism as botulinum toxin — SNARE complex inhibition at the neuromuscular junction — but through competitive binding rather than enzymatic cleavage. It is less potent than injected botulinum toxin (achieving ~50% wrinkle reduction vs. near-complete paralysis), but works non-invasively through topical application without needles, neurotoxin risks, or downtime.

How does Argireline compare to botulinum toxin injections?

Botulinum toxin provides stronger, more immediate wrinkle reduction (visible in 3-7 days, lasting 3-4 months) but requires injection, carries neurotoxin risks, and costs significantly more. Argireline provides gradual improvement over 4 weeks with approximately 50% wrinkle reduction, but is non-invasive, inexpensive, and has an excellent safety profile. Many practitioners recommend Argireline between injection appointments to extend results.

Can Argireline penetrate the skin effectively given its size?

At 887 Da, Argireline is relatively large for topical absorption. It primarily acts in the stratum corneum and superficial epidermis, with limited deeper penetration (0.22-0.54% skin penetration). Advanced formulation vehicles (O/W emulsions, W/O/W emulsions) improve delivery. Despite limited deep penetration, clinical efficacy is clearly demonstrated, likely through surface-level neuromuscular modulation.

Are the wrinkle-reducing effects permanent?

No. Argireline's effects are maintained only with continued application. Upon discontinuation, SNARE complex function normalizes and expression lines gradually return to their pre-treatment state within approximately 4-8 weeks. Consistent twice-daily application is needed to maintain wrinkle reduction.

What areas of the face respond best to Argireline?

Argireline works best on dynamic expression wrinkles — lines caused by repeated muscle movement. The most responsive areas include crow's feet (lateral periorbital lines), horizontal forehead lines, and glabellar frown lines. It is less effective on static wrinkles caused by photoaging or loss of skin elasticity unrelated to muscle contraction.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Acetyl Hexapeptide-3 (Argireline), on one page.

Acetyl Hexapeptide-3 (Argireline) dosing protocol

Medical disclaimer

Acetyl Hexapeptide-3 (Argireline) is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026

5 % – 10 % Twice daily (morning and evening) · onset 1-2 weeks
Open the Acetyl Hexapeptide-3 (Argireline) calculatorAcetyl Hexapeptide-3 (Argireline) calculator